BIRC5 and acute lymphoblastic leukemia: Therefore, a phase I study combining the survivin mRNA antagonist EZN-3042 with re-induction chemotherapeutic drugs has been developed for pediatric relapsed B-ALL patients (NCT01186328) [125].